James J. Kelly, former president and CEO of Carl Zeiss, has been selected as the new president and CEO of the Food and Drug Law Institute (FDLI), a nonprofit international organization of food, drug and medical device manufacturers, attorneys, regulators and consultants. Before becoming president and CEO at Zeiss, the US subsidiary of the German-based manufacturer of precision optics, Kelly held a variety of executive positions, including general manager of its Microscopy Group, general counsel and vice-president. Previously, Kelly was vice president, general counsel and head of human resources at Siemens Medical. A graduate of St. Joseph's University and Villanova Law School, Kelly began his career in the general practice of law in New York City. He is a member of the New York State Bar and former vice-chairman of the German-American Chamber of Commerce in New York. Kelly became FDLI president and CEO on Aug., 14, succeeding Jerome A. Halperin, who stepped down after five years at the helm of the Washington, DC-based group. FDLI publishes the Food and Drug Law Journal, a bimonthly magazine, Update, the FDA Directory and dozens of publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field.